|Mr. Joseph Hernandez M.S.,MBA||Founder, Exec. Chairman, CEO & CFO||N/A||N/A||44|
|Dr. Louis A. Tartaglia Ph.D.||Chief Exec. Officer, Pres and Member of The Board of Directors||N/A||N/A||53|
|Mr. Michael E. Solomon Ph.D.||Chief Operating Officer||N/A||N/A||N/A|
|Dr. Dean A. Falb Ph.D.||Chief Scientific Officer, Scientific Consultant & Scientific Advisor||N/A||N/A||50|
|Dr. Jasbir Seehra Ph.D.||Chief Scientific Officer and Member of Scientific Advisory Board||N/A||N/A||N/A|
Ember Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company focuses on the clinical application of bone morphogenetic protein-7 (BMP-7) to develop regenerative medicines for the disease modification of osteoarthritis (OA), reversal of insulin resistance, and the inhibition and reversal of organ fibrosis in diseases, such as chronic kidney disease (CKD) and Alports syndrome, as well as metabolic diseases, including obesity and type 2 diabetes. Its lead BMP-7 product candidates include MT-006, which has completed Phase 2a clinical trial for targeting OA; MT-007 that has completed Preclinical trial for CKD and Alport syndrome; MT-008, a Preclinical trial completed candidate for Alport syndrome; and MT-009, a Preclinical trial completed candidate for metabolic disease. The company also holds approximately 450 patents covering BMP-7 and its related family of BMPs, variants, novel formulations, delivery technologies, associated clinical data, and manufactured material with current good manufacturing practice. Ember Therapeutics, Inc. was founded in 2010 and is headquartered in New York, New York.
Ember Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.